import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "cjc-1295-ipamorelin-stack-jun21-2026",
  title: "CJC-1295 + Ipamorelin: Growth Hormone Research Stack (2026)",
  description:
    "A research-focused overview of the CJC-1295 and Ipamorelin combination — complementary mechanisms targeting the GHRH and ghrelin receptor pathways, published data on synergistic GH stimulation, and protocol design considerations for GH-axis researchers.",
  category: "Peptide Research",
  readMinutes: 12,
  publishedAt: "2026-06-21",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Among the most studied peptide combinations in growth hormone research, the CJC-1295 and Ipamorelin stack occupies a unique position. These two compounds act on separate but complementary pathways within the somatotropic axis, and their co-administration has been a recurring subject in pre-clinical and clinical investigation. Understanding the rationale for this combination requires understanding both compounds individually and the system they act on.",
    },
    {
      type: "heading",
      text: "Understanding the Somatotropic Axis",
    },
    {
      type: "paragraph",
      text: "Growth hormone (GH) secretion is regulated by two primary hypothalamic signals: Growth Hormone-Releasing Hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. A third pathway — the ghrelin receptor (GHS-R1a) — provides an independent stimulatory signal. Compounds targeting different nodes in this system can produce synergistic rather than merely additive effects. This is the biological rationale underlying the CJC-1295/Ipamorelin combination.",
    },
    {
      type: "heading",
      text: "CJC-1295: A GHRH Analog",
    },
    {
      type: "paragraph",
      text: "CJC-1295 is a synthetic analog of GHRH. Its distinguishing feature is a Drug Affinity Complex (DAC) modification in its most studied form, which covalently binds to circulating albumin. This extends its half-life from minutes to approximately 6–8 days, enabling sustained elevation of GH secretion patterns rather than the acute pulses produced by shorter-acting GHRH analogs.",
    },
    {
      type: "subheading",
      text: "Key Research Findings",
    },
    {
      type: "paragraph",
      text: "A 2006 study published in the Journal of Clinical Endocrinology & Metabolism (Teichman et al.) administered CJC-1295 to healthy adult subjects and documented dose-dependent increases in plasma GH up to 10-fold above baseline in some subjects, sustained IGF-1 elevation lasting 9–11 days after a single dose, and preservation of pulsatile GH release. This pulsatility preservation is a notable distinction from exogenous GH administration, which typically suppresses endogenous production.",
    },
    {
      type: "table",
      headers: ["Parameter", "CJC-1295 (DAC)", "CJC-1295 (no DAC)"],
      rows: [
        ["Target receptor", "GHRHR on somatotrophs", "GHRHR on somatotrophs"],
        ["Half-life", "~6–8 days", "~30 minutes"],
        ["GH pattern", "Sustained elevation", "Acute pulse"],
        ["IGF-1 effect", "Prolonged elevation", "Transient elevation"],
      ],
    },
    {
      type: "heading",
      text: "Ipamorelin: A Selective GHS",
    },
    {
      type: "paragraph",
      text: "Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) and selective agonist of the ghrelin receptor (GHS-R1a). It was developed as a research compound due to its high selectivity — unlike earlier GHS compounds such as GHRP-6, Ipamorelin shows minimal effect on cortisol, prolactin, or ACTH in studied doses, making it a cleaner tool for GH-axis research.",
    },
    {
      type: "subheading",
      text: "Selectivity Profile",
    },
    {
      type: "paragraph",
      text: "A study by Elbrønd et al. (1999) in swine demonstrated significant dose-dependent GH release with Ipamorelin, with a favorable selectivity profile compared to GHRP-2. Research has consistently documented robust GH pulse stimulation comparable to GHRP-6 at equivalent molar doses, with reduced off-target hormone release. This selectivity distinction matters for experimental design: when cortisol or prolactin elevation would confound outcomes, Ipamorelin is preferred over less selective GHS compounds.",
    },
    {
      type: "heading",
      text: "The Rationale for Stacking CJC-1295 and Ipamorelin",
    },
    {
      type: "paragraph",
      text: "The combination of a GHRH analog with a GHS targets two independent but synergistic pathways. The GHRH pathway (CJC-1295) acts via cAMP-mediated mechanisms at the somatotroph, while the GHS-R1a pathway (Ipamorelin) acts via phospholipase C and calcium mobilization. These convergent but mechanistically distinct signals on somatotrophs produce greater GH release than either compound alone at the same individual doses.",
    },
    {
      type: "subheading",
      text: "Somatostatin Suppression Effect",
    },
    {
      type: "paragraph",
      text: "GHS-R1a agonists including Ipamorelin also suppress somatostatin release from the hypothalamus. Since somatostatin is the primary brake on GH secretion, this suppression amplifies the stimulatory effect of CJC-1295. The net result is GH pulse amplitude greater than what either pathway stimulation achieves alone — a physiologically plausible mechanism for the observed synergy in combination research.",
    },
    {
      type: "heading",
      text: "Research Protocol Considerations",
    },
    {
      type: "subheading",
      text: "Timing",
    },
    {
      type: "paragraph",
      text: "Ipamorelin's short half-life (~2 hours) makes it suitable for acute pulse protocols. It is commonly co-administered with CJC-1295 to produce a defined GH pulse against the elevated baseline created by the GHRH analog. Circadian timing is relevant: GH secretion peaks during sleep in physiological conditions, and this pattern is reflected in research timing protocols.",
    },
    {
      type: "subheading",
      text: "Desensitization",
    },
    {
      type: "paragraph",
      text: "Long-term continuous GHS-R1a stimulation produces receptor desensitization, as documented with other GHS compounds. Research protocols typically incorporate cycling periods to maintain receptor sensitivity. CJC-1295's extended half-life (DAC form) is particularly relevant here — its sustained activity means effective duration of action extends well beyond the injection interval, which must be factored into protocol design.",
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "The CJC-1295/Ipamorelin combination represents a well-studied approach to dual-pathway GH axis stimulation in research contexts. The mechanistic rationale is supported by published data, the selectivity profile of Ipamorelin reduces off-target hormonal noise, and the complementary half-lives allow for both sustained GH elevation (CJC-1295) and defined acute pulsatility (Ipamorelin). For researchers studying GH secretion, body composition, or downstream IGF-1 effects, this stack offers one of the more extensively documented research frameworks available.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use. This content is educational and does not constitute medical advice.",
    },
  ],
};
